Company
Abbott Laboratories
NYSE:ABT
Abbott Laboratories is a global healthcare company. The company’s portfolio of technologies spans the spectrum of healthcare, with businesses and products in diagnostics, medical devices, nutritional and branded generic medicines.
58 stories
Nasdaq notches new closing record, Netflix slips after earnings
The overall tone remains positive, even if gains have been modest
Archive
Nasdaq, S&P 500 close at records as retail data, earnings power rally
US retail sales rose 0.6% in June, beating expectations for a 0.1% gain
Archive
S&P 500 closes at new record high for fourth day in a row
The S&P 500 finished up 0.1% at 4,868.55 points. The Nasdaq gained 0.4% at 15,482 points while the Dow Jones retreated by 0.3% to 37,807 points
Todos Medical to supply New York lab with COVID-19 PCR testing equipment and supplies
Under the $4.5 million, 12-month contract, Todos said it will supply automated extraction machines, liquid handlers and PCR machines
Abbott stock rising as FDA greenlights 15-minute COVID-19 test
The group says it can make 1mln of the US$5 antigen tests per day initially and it plans to ramp up shipments up to a rate of 50mln tests per month by October.
Abbott Laboratories' Covid-19 antibody test approved by UK authorities
US authorities warned on Thursday that the kit may deliver inaccurate results, allegation refuted by the company
Nemaura Medical has a big winner in its painless SugarBEAT glucose monitor
The medtech company is eyeing explosive growth with SugarBEAT, already launching in the UK, followed by the rest of Europe
Ascendiant Capital Markets initiates coverage of Nemaura Medical with Buy rating, $3.25 price target
In addition, Acorn Management analyst Peter Wright says research shows the company's SugarBEAT scores over other glucose monitors on ‘multiple counts’ including affordability and cost
Nemaura Medical rounds out successful human factors usability study for sugarBEAT glucose monitor
This brings the England-based medical technology company a step closer to submitting its medical device application to the FDA for sugarBEAT
Nemaura Medical adds new predictive alert function to its sugarBEAT glucose monitor
CEO Faz Chowdhury says adding the alerts and alarms based on predictive algorithms as part of the current CE review process avoids the need for a subsequent CE application
Nemaura on track for FDA's De Novo submission for sugarBEAT glucose monitor in 2Q
SugarBEAT which has been honed and perfected over seven years is expected to receive CE approval in the UK soon
Nemaura rises after supply deal for its SugarBEAT glucose monitor in Mideast
It’s a strategic move to crack open the wealthy markets of Saudi Arabia, Oman, Kuwait and Bahrain
Nemaura completes clinical studies for De Novo submission to FDA for sugarBEAT glucose monitor
The company plans to apply to the FDA in the first quarter of 2019, which could speed up sugarBEAT’s arrival on American shores
Investments and investor services
Wincanton on the right road as strong cash flow whittles away debt
A look at the day's poppers and droppers, including JD Wetherspoon, Gattaca, Renewi, AdEPT, The Works, Coca-Cola HBC and Micro Focus
Archive
Proactive news snapshot: Immotion Group, NetScientific, AdEPT Technology …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
FTSE 100 closes higher ahead of Federal Reserve meeting
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Nemaura develops predictive algorithms, alarm functionality for its sugarBEAT glucose monitor
The innovation will make sugarBEAT more appealing and useful to insulin users
Hardware & electrical equipment
Tekcapital's blue-chip hires
The top teams at Tekcapital's investee companies exude quality
OptiBiotix to bring cholesterol reduction product to India with new agreement
The agreement was signed with Akums Drugs and Pharmaceuticals Ltd, a leading contract manufacturer of food and drug supplements in India
Abbott Laboratories posts higher-than-estimated 1Q profit on diagnostics business
Revenue at the medical-products group advanced 17% to US$7.39bln
Archive
Proactive news snapshot Keyword Studios, Directa Plus, Concepta …
A glance at some of the day's highlights from the Proactive Investors newswire
AfriTin Mining gains on MoU with MRI Trading
A look at some of the top risers and fallers in London today
FTSE 100 closes positively as Wall Street rebounds, but Russian stocks hit
The UK blue chip share index finished around 11 points higher at 7,194
Smith & Nephew says former Alere boss, Namal Nawana to join as chief executive from next month
Nawana was most recently chief executive of medical diagnostics company Alere, overseeing its US$5.3bn acquisition by Abbott Laboratories in 2017
Surmodics surges as it inks commercialisation deal with Abbott for SurVeil PAD treatment
Abbott is paying US$25mln upfront plus up to a further US$67mln in milestone payments to Surmodics for the exclusive worldwide commercialisation rights for SurVeil
Archive
Proactive news snapshot: Highlands Natural Resources, ANGLE , Redx Pharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Highland Gold Mining boosted by updated mineral resource estimate for flagship Kekura project
A look at some of the biggest risers and fallers in the London market on Tuesday
ANGLE to collaborate with Abbott Laboratories on metastatic breast cancer study
Abbott will provide its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 FDA study for FISH analysis of circulating tumour cells in the form of a research grant
FTSE 100 closes 2.64% lower as stock chaos continues
FTSE 100 closed 2.64% lower, or 193 points, at 7,141 amid chaotic US trading
Strong Humira sales lead to Q4 beat for AbbVie
The drugmaker also upped its earnings forecasts for 2018 following the strong performance in the final few months of 2017
Abbott Labs reports solid fourth quarter earnings, although headline numbers hit by US tax changes
The drugs group reported a loss per share of 50 US cents a share in the fourth quarter, mainly because of a US$1.46bn charge related to the corporate tax reforms
Hardware & electrical equipment
Abbott Laboratories, Apple Inc, Lennar and Wynn Resorts Ltd - PRE-MARKET
Proactive takes a look at pre-market trade in New York, and picks out some highlights
Alnylam Pharmaceuticals, American Express Company, Abbott Laboratories and more
Proactive takes a look at what was piquing interest ahead of the bell in New York
Twitter, Facebook, Advanced Accelerator Applications and more - AFTER HOURS
We take a look at what happened after the bell in New York on Wall Street
Medical supply sector in focus after huge C.R. Bard, Becton combination
Bard will be bought by fellow titan Becton, Dickinson and Co after the pair agreed to combine in an eye watering $24bn deal.
Benchmarks now up on the week after strong GDP data
Though it seemed improbable at the close of trading on Monday, U.S. benchmarks are now up on the week. Sentiment has been boosted by a strong showing overnight in Asian markets and much better than expected US gross domestic product figures
Benchmarks now up on the week after strong GDP data
The US economy grew more strongly than expected in the third quarter, and although this may make a rate hike more likely next month, investors are betting that this week's global stock market turmoil will stay the Fed's hand.
Relief rally moves into second day
Gross domestic product numbers were much better than expected giving a lift to a market already buoyed by Shanghai's strength overnight.
US stock have their mojo back
A strong showing this morning in Shanghai and some comforting words from Federal Reserve member William Dudley look set to keep investors in a more upbeat frame of mind.
Abbott Laboratories denies it is eyeing St Jude
Shares in acquisitive drugs maker Abbott perked up after it denied an FT report that it is preparing a bid for St Jude Medical.
Investments and investor services
US stocks further lifted by strong GDP data
“A healthy upwards revision to US GDP should act as a much needed soothing balm for investors after the turbulence of this week," said Nancy Curtin, chief investment officer, Close Brothers Asset Management